Rebecca Epperly

Dr. Rebecca Epperly

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNikhil Hebbar
Nikhil Hebbar
RERebecca Epperly
Rebecca Epperly
AVAbishek Vaidya
Abishek Vaidya
UTUnmesha Thanekar
Unmesha Thanekar
SMSarah E. Moore
Sarah E. Moore
MVMireya Paulina Velasquez
Mireya Paulina Velasquez
Developing CAR T cells for acute myeloid leukemia (AML) has been hampered by a paucity of targets that are expressed on AML blasts and not on hematopoietic progenitor cells (HPCs). Here we demonstrate that GRP78 is expressed on the cell surface of primary AML blasts but not HPCs. To target GRP78, we generate T cell expressing a GRP78-specific peptide-based CAR, which show evidence of minimal fratricide post activation/transduction and antigen-dependent T cell differentiation. GRP78-CAR T cells recognize and kill GRP78-positive AML cells without toxicity to HPCs. In vivo, GRP78-CAR T cells have significant anti-AML activity. To prevent antigen-dependent T cell differentiation, we block CAR signaling and GRP78 cell surface expression post activation by using dasatinib during GRP78-CAR T cell manufacturing. This significantly improves their effector function in vitro and in vivo. Thus, targeting cell surface GRP78-positive AML with CAR T cells is feasible, and warrants further active exploration.

15 January 2025 in Blood Advances
Verified
Journal Article
Open access
DZDua’a Zandaki
Dua’a Zandaki
SSSubodh Selukar
Subodh Selukar
YBYu Bi
Yu Bi
YLYing Li
Ying Li
MZMegan Zinsky
Megan Zinsky
ACAimee C
Aimee C
Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are complications of CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy. The Endothelial Activation and Stress Index (EASIX) and modified EASIX (m-EASIX) scores have been retrospectively proven to be predictive of CRS and ICANS in adult CAR T-cell recipients. However, these scores have not been evaluated in pediatric cohorts. We retrospectively report on 76 pediatric and adolescent and young adult (AYA) patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with CD19-CAR T cells at St. Jude Children’s Research Hospital or Johns Hopkins Hospital. Data included patient, disease, and treatment characteristics. EASIX and m-EASIX scores were calculated at days –5 before, 0, and +3 after CAR T-cell infusion. CRS and ICANS occurred in 47 and 17 patients, respectively. At all evaluated time points, the median EASIX scores were higher for patients who developed severe CRS and any grade ICANS, and the median m-EASIX scores were higher in patients who developed severe CRS and severe ICANS than those with no/mild CRS/ICANS. Receiver operating characteristic curve analysis showed that both scores were strong predictors of CRS, especially severe CRS, at all time points. Any grade and severe ICANS were best predicted by both scores at day +3. m-EASIX uniformly outperformed EASIX, except for predicting any grade ICANS. Our results validate the potential utility of EASIX and m-EASIX scores for predicting CAR T-cell–related complications for pediatric and AYA patients.

17 March 2024 in EJC Paediatric Oncology
Verified
Journal Article
Open access
RERebecca Epperly
Rebecca Epperly
SGStephen Gottschalk
Stephen Gottschalk
CDChristopher DeRenzo
Christopher DeRenzo
Despite intensive therapies, pediatric patients with relapsed or refractory solid tumors have poor outcomes and need novel treatments. Immune therapies offer an alternative to conventional treatment options but require the identification of differentially expressed antigens to direct antitumor activity to sites of disease. B7-H3 (CD276) is an immune regulatory protein that is expressed in a range of malignancies and has limited expression in normal tissues. B7-H3 is highly expressed in pediatric solid tumors including osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Wilms tumor, neuroblastoma, and many rare tumors. In this article we review B7-H3-targeted chimeric antigen receptor (B7-H3-CAR) T cell therapies for pediatric solid tumors, reporting preclinical development strategies and outlining the landscape of active pediatric clinical trials. We identify challenges to the success of CAR T cell therapy for solid tumors including localizing to and penetrating solid tumor sites, evading the hostile tumor microenvironment, supporting T cell expansion and persistence, and avoiding intrinsic tumor resistance. We highlight strategies to overcome these challenges and enhance the effect of B7-H3-CAR T cells, including advanced CAR T cell design and incorporation of combination therapies.

17 February 2020 in Children
Verified
Journal Article
Open access
PDF file
RERebecca Epperly
Rebecca Epperly
SGStephen Gottschalk
Stephen Gottschalk
MVMireya Paulina Velasquez
Mireya Paulina Velasquez
Outcomes for pediatric patients with acute myeloid leukemia (AML) remain poor, highlighting the need for improved targeted therapies. Building on the success of CD19-directed immune therapy for acute lymphocytic leukemia (ALL), efforts are ongoing to develop similar strategies for AML. Identifying target antigens for AML is challenging because of the high expression overlap in hematopoietic cells and normal tissues. Despite this, CD123 and CD33 antigen targeted therapies, among others, have emerged as promising candidates. In this review we focus on AML-specific T cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cells. We review antigens being explored for T cell-based immunotherapy in AML, describe the landscape of clinical trials upcoming for bispecific antibodies and CAR T cells, and highlight strategies to overcome additional challenges facing translation of T cell-based immunotherapy for AML.

21 June 2023 in Hematology/Oncology Clinics of North America
Verified
Journal Article
Closed access
RERebecca Epperly
Rebecca Epperly
VGVictoria M. Giordani
Victoria M. Giordani
LMLekha Mikkilineni
Lekha Mikkilineni
NSNirali N. Shah
Nirali N. Shah

10 June 2023 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
DLDeena Levine
Deena Levine
RERebecca Epperly
Rebecca Epperly
GCGriffin Collins
Griffin Collins
ATAimee C. Talleur
Aimee C. Talleur
BMBelinda Mandrell
Belinda Mandrell
JBJustin N. Baker
Justin N. Baker